

**Technescan™ HDP**  
**(Kit for the Preparation of Technetium Tc 99m Oxidronate Injection)**  
*For Intravenous Use*


## DESCRIPTION

### Drug Characteristics

Technescan™ HDP (kit for the preparation of technetium Tc 99m oxidronate injection) is a radioactive diagnostic drug for intravenous use after radiolabeling with sodium pertechnetate Tc 99m injection.

Each vial contains 3.15 mg oxidronate sodium and 0.258 mg, minimum, stannous chloride (SnCl<sub>2</sub>•2H<sub>2</sub>O), 0.297 mg, theoretical, stannous chloride (SnCl<sub>2</sub>•2H<sub>2</sub>O) with 0.343 mg, maximum, tin chloride [stannous and stannic] dihydrate as SnCl<sub>2</sub>•2H<sub>2</sub>O, and the following inactive ingredients: 0.84 mg gentisic acid as a stabilizer and 30 mg sodium chloride. The pH is adjusted with hydrochloric acid and/or sodium hydroxide. The pH of the radiolabeled drug is between 4.0 and 5.5. The vial contains a sterile, non-pyrogenic, lyophilized powder packaged under nitrogen.

The chemical structure of oxidronate sodium is:



The structure of the technetium Tc 99m oxidronate complex is unknown.

### Nuclear Physical Characteristics

Technetium-99m decays by isomeric transition with a physical half-life of 6.02 hours. The principal photon that is useful for detection and imaging is listed in Table 1.

**Table 1. Principal Radiation Emission Data**

Radiation	Mean % per Disintegration	Energy (keV)
Gamma-2	89.07	140.5

The specific gamma ray constant for technetium-99m is 0.795 R/hr-mCi at 1 cm. The first half-value layer is 0.023 cm of lead (Pb). A range of values for the relative attenuation of the radiation emitted by this radionuclide that results from interposition of various thicknesses of Pb is shown in Table 2. For example, the use of 0.27 cm of Pb will attenuate the external radiation emitted by a factor of about 1,000.

**Table 2. Radiation Attenuation by Lead Shielding**

Shield Thickness (Pb) cm	Coefficient of Attenuation
0.023	0.5
0.09	10 <sup>-1</sup>
0.18	10 <sup>-2</sup>
0.27	10 <sup>-3</sup>

To correct for physical decay of this radionuclide, the fractions that remain at selected time intervals after the time of calibration are shown in Table 3.

**Table 3. Physical Decay Chart: Technetium-99m, Half-Life 6.02 Hours**

Hours	Fraction Remaining	Hours	Fraction Remaining
0*	1	7	0.447
1	0.891	8	0.398
2	0.794	9	0.355
3	0.708	10	0.316
4	0.631	11	0.282
5	0.562	12	0.251
6	0.501		

\* Calibration time

### **CLINICAL PHARMACOLOGY**

During the 24 hours following injection, technetium Tc 99m oxidronate is cleared from blood and other non-osseous tissues and accumulates in the skeleton and urine in humans. Blood levels are about 10% of the injected dose at one hour post-injection and continue to fall to about 6%, 4% and 3% at 2, 3, and 4 hours, respectively. When measured at 24 hours following its administration, skeletal retention is approximately 50% of the injected dose. Technetium Tc 99m oxidronate exhibits its greatest affinity for areas of altered osteogenesis and actively metabolizing bone.

### **INDICATIONS AND USAGE**

Technescan HDP, after radiolabeling with sodium pertechnetate Tc 99m, is indicated for skeletal imaging to demonstrate areas of altered osteogenesis in adult and pediatric patients.

### **CONTRAINDICATIONS**

None known.

## WARNINGS

Technetium Tc 99m oxidronate may cause life-threatening hypersensitivity reactions. Have cardiopulmonary resuscitation equipment and personnel available and monitor all patients for hypersensitivity reactions. (See **ADVERSE REACTIONS**.)

Technetium Tc 99m oxidronate is known to complex cations such as calcium. Particular caution should be used with patients who have or who may be predisposed to hypocalcemia.

The biodistribution of technetium Tc 99m oxidronate may be altered in the presence of high levels of certain cations (iron, calcium, and aluminum). This may result in reduced uptake of radionuclide in the skeleton and increased extraosseal uptake, which may potentially degrade imaging quality. High levels of these cations may be caused by concomitant medications or medical conditions (e.g., iron overload, hypercalcemia, etc.). Most cases were observed after iron infusion. (See **PRECAUTIONS, Drug Interactions**.)

## PRECAUTIONS

### General

Technetium Tc 99m oxidronate contributes to a patient's overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk of cancer. Ensure safe drug handling to protect patients and healthcare providers from unintentional radiation exposure. (See **DOSAGE AND ADMINISTRATION, Radiation Safety-Drug Handling**.) To minimize radiation dose to the bladder, encourage patients to drink fluids before and after administration and to void immediately before the examination and as often thereafter as possible for the next 4 to 6 hours.

### Drug Interactions

The biodistribution of technetium Tc 99m oxidronate may be altered in the presence of high levels of certain cations (iron, calcium, and aluminum). This may result in reduced uptake of radionuclide in the skeleton and increased extraosseal uptake, which may potentially degrade imaging quality. In patients with high levels of these cations caused by concomitant medications, particularly patients receiving iron infusions, consider performing an imaging study with technetium Tc 99m oxidronate injection once the cation levels have normalized (e.g., after 3 to 5 half-lives of the cation). (See **WARNINGS**.)

### Carcinogenesis, Mutagenesis, Impairment of Fertility

No long-term animal studies have been performed to evaluate carcinogenic or mutagenic potential or whether technetium Tc 99m oxidronate affects fertility in males and females.

## **Pregnancy**

Animal reproduction studies have not been conducted with technetium Tc 99m oxidronate. It is also not known whether technetium Tc 99m oxidronate can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity.

All radiopharmaceuticals, including Technescan HDP, have the potential to cause fetal harm depending on the fetal stage of development and the magnitude of the radiation dose. If considering Technescan HDP administration to a pregnant woman, inform the patient about the potential for adverse pregnancy outcomes based on the radiation dose from technetium Tc 99m oxidronate and the gestational timing of exposure.

## **Nursing Mothers**

Technetium-99m is excreted in human milk during lactation, therefore formula feedings should be substituted for breast feedings.

## **Pediatric Use**

Technescan HDP, after radiolabeling with sodium pertechnetate Tc 99m, is indicated for skeletal imaging to demonstrate areas of altered osteogenesis in pediatric patients.

The relatively higher effective dose and radiation exposure of the epiphyses in growing bone should be considered in pediatric patients. (See **DOSAGE AND ADMINISTRATION, Radiation Dosimetry**).

## **Geriatric Use**

This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

## **ADVERSE REACTIONS**

The following adverse reactions associated with the use of Technescan HDP have been reported: hypersensitivity reactions, including life-threatening reactions, as well as nausea, vomiting, and injection site reactions.

## **OVERDOSAGE**

In the event of the administration of an overdose of Technetium Tc 99m Oxidronate Injection, encourage patients to drink fluids and void frequently to reduce the radiation dose to the patient.

## DOSAGE AND ADMINISTRATION

### Radiation Safety – Drug Handling

After radiolabeling of Technescan HDP, the reaction vial contains Technetium Tc 99m Oxidronate Injection. Handle Technetium Tc 99m Oxidronate Injection with appropriate safety measures to minimize radiation exposure. (See **PRECAUTIONS, General.**) Use waterproof gloves, effective radiation shielding, and other appropriate safety measures when preparing and handling Technetium Tc 99m Oxidronate Injection.

Radiopharmaceuticals should be used by or under the control of healthcare providers who are qualified by specific training and experience in the safe use and handling of radionuclides, and whose experience and training have been approved by the appropriate governmental agency authorized to license the use of radionuclides.

### Recommended Dosage

#### Adults

The recommended amount of radioactivity of Technetium Tc 99m Oxidronate Injection in adults is 555 MBq (15 mCi) with a range of 370 MBq to 740 MBq (10 mCi to 20 mCi).

The maximum dose of oxidronate sodium in adults is 2 mg.

#### Pediatric Patients

The recommended amount of radioactivity of Technetium Tc 99m Oxidronate Injection in pediatric patients is 7.4 MBq/kg to 13 MBq/kg (0.20 mCi/kg to 0.35 mCi/kg).

The recommended minimum and maximum activity in pediatric patients are 37 MBq (1 mCi) and 740 MBq (20 mCi), respectively. The maximum dose of oxidronate sodium in pediatric patients is 2 mg.

### Administration Instructions

- Measure the patient dose with a dose calibrator just prior to administration.
- Administer the dose intravenously by slow injection 1 hour to 4 hours before imaging.
- To minimize radiation dose to the bladder, encourage the patients to drink fluids before and after administration of Technetium Tc 99m Oxidronate Injection and to void immediately before the examination and as often thereafter as possible for the next 6 hours. (See **PRECAUTIONS, General.**)

## Directions for Drug Preparation

### Procedural Precautions

- The contents of the vial are intended only for use in the preparation of Technetium Tc 99m Oxidronate Injection and are NOT to be administered directly to the patient.
- The components of the kit are sterile and non-pyrogenic. Follow the directions carefully and adhere to strict aseptic procedures during preparation.
- Sodium pertechnetate Tc 99m injection that contains an oxidizing agent or 0.9% sodium chloride injection containing preservatives is not suitable for use in the preparation of Technetium Tc 99m Oxidronate Injection.
- Wear waterproof gloves during the entire preparation procedure and during subsequent patient dose withdrawals from the reaction vial.
- Make all transfers of sodium pertechnetate Tc 99m injection using an adequately shielded syringe.
- Keep the prepared Technetium Tc 99m Oxidronate Injection in the lead vial shield with fitted lead cover in place during the useful life of the radioactive preparation. Make all withdrawals and injection of the Technetium Tc 99m Oxidronate Injection with an adequately shielded syringe.
- If the dose is for a single adult patient or for pediatric patients, see Directions for the Preparation of a Single Adult Dose or Pediatric Dose(s).

### Directions for the Preparation of Adult Doses

1. Remove the plastic disc from the Technescan HDP vial and swab the rubber septum with an alcohol swab or a suitable bacteriostatic agent to disinfect the surface.
2. Place the vial in a lead vial shield. Add 3 mL to 6 mL of sodium pertechnetate Tc 99m injection and secure with a fitted lead cover. In choosing the amount of sodium pertechnetate Tc 99m injection radioactivity to be used, the number of doses desired, the activity of each dose, and radioactive decay must be taken into account. The recommended maximum activity of sodium pertechnetate Tc 99m injection to be added to the vial is 11,100 MBq (300 mCi).
3. Shake the vial gently, for approximately 30 seconds, to ensure complete dissolution.
4. Using proper shielding, visually inspect the reaction vial. The resulting solution should be clear and free of particulate matter. If not, do not use the product.

5. Assay the product in a suitable dose calibrator and record the time, date of preparation, and the activity of the Technetium Tc 99m Oxidronate Injection on the radioassay information label and affix it to the vial.
6. Determine the radiochemical purity prior to administration.
7. Store the reaction vial upright in the lead vial shield with fitted lead cover in place at room temperature, 20°C to 25°C (68° to 77°F). Use within 8 hours of radiolabeling.
8. Dispose of unused material in a safe manner in accordance with applicable regulations.

Directions for the Preparation of a Single Adult Dose or Pediatric Dose(s)

- a. Remove the plastic cap from the Technescan HDP vial and swab the rubber septum with an alcohol swab or a suitable bacteriostatic agent to disinfect the surface.
- b. Add 3 mL to 6 mL of 0.9% sodium chloride injection. Shake the vial gently for approximately 30 seconds to assure complete dissolution.
- c. Withdraw and discard all but approximately 1 mL of the solution.
- d. Place the vial in a lead vial shield. Add an appropriate amount of sodium pertechnetate Tc 99m injection for a single adult dose or for one or more pediatric doses and shake gently. No more than 1,480 MBq (40 mCi) should be added to the vial when preparing multiple pediatric doses.
- e. Proceed with steps 4 through 8 above.

**Radiation Dosimetry**

Estimated absorbed radiation doses from an intravenous injection of Technetium Tc 99m Oxidronate Injection are shown in Table 4.

**Table 4. Estimated Absorbed Radiation Doses in Organs and Tissues in Patients Who Received Technetium Tc 99m Oxidronate Injection**

Organ/Tissue	Absorbed Dose* per Unit Activity Administered (mGy/MBq)				
	Adults	15 years	10 years	5 years	1 year
Adrenals	0.0021	0.0026	0.0038	0.0058	0.0110
Bone surfaces	0.0340	0.0150	0.0230	0.0380	0.0820
Brain	0.0017	0.0020	0.0028	0.0042	0.0059
Breast	0.0007	0.0009	0.0013	0.0021	0.0040
Gallbladder wall	0.0014	0.0018	0.0033	0.0043	0.0065

GI tract					
Stomach	0.0012	0.0014	0.0024	0.0036	0.0064
Small intestine wall	0.0022	0.0028	0.0043	0.0061	0.0093
Colon wall	0.0027	0.0034	0.0052	0.0072	0.0100
Upper large intestine wall	0.0019	0.0024	0.0038	0.0057	0.0087
Lower large intestine wall	0.0038	0.0047	0.0071	0.0092	0.0130
Heart	0.0012	0.0015	0.0022	0.0033	0.0059
Kidneys	0.0072	0.0087	0.0120	0.0180	0.0310
Liver	0.0012	0.0016	0.0024	0.0036	0.0064
Lungs	0.0012	0.0016	0.0023	0.0035	0.0067
Muscles	0.0018	0.0022	0.0033	0.0047	0.0077
Esophagus	0.0010	0.0013	0.0019	0.0029	0.0051
Ovaries	0.0036	0.0045	0.0065	0.0086	0.0120
Pancreas	0.0016	0.0020	0.0030	0.0045	0.0079
Red marrow	0.0059	0.0054	0.0088	0.0170	0.0360
Skin	0.0010	0.0013	0.0019	0.0030	0.0053
Spleen	0.0014	0.0018	0.0027	0.0044	0.0077
Testes	0.0024	0.0033	0.0054	0.0085	0.0100
Thymus	0.0010	0.0013	0.0019	0.0029	0.0051
Thyroid	0.0013	0.0015	0.0022	0.0034	0.0054
Urinary bladder wall	0.0470	0.0590	0.0870	0.1100	0.1300
Uterus	0.0062	0.0075	0.0110	0.0140	0.0180
Remaining organs	0.0019	0.0023	0.0034	0.0050	0.0077
<b>Effective Dose (mSv/MBq)</b>	<b>0.0049</b>	<b>0.0057</b>	<b>0.0086</b>	<b>0.0120</b>	<b>0.0180</b>

\*For normal skeletal uptake and kidney function

## HOW SUPPLIED

Technescan HDP (kit for the preparation of technetium Tc 99m oxidronate injection) contains 3.15 mg oxidronate sodium as a white lyophilized powder in a multiple-dose vial.

Technescan HDP is available as:

- 5 vials per carton (NDC 69945-091-20)
- 30 vials per carton (NDC 69945-091-40)

Before radiolabeling, store at 20°C to 25°C (68°F to 77°F) [see USP Controlled Room Temperature].

After radiolabeling, store vial upright in appropriate shielding at 20°C to 25°C (68°F to 77°F) [see USP Controlled Room Temperature]. Use within 8 hours of radiolabeling.

Dispose of unused products in accordance with appropriate regulations.

This reagent kit is for distribution to persons licensed by the U.S. Nuclear Regulatory Commission or the relevant regulatory authority of an Agreement State.

Manufactured by:  
Curium US LLC  
2703 Wagner Place  
Maryland Heights, MO 63043

Made in USA

©2025 Curium US LLC. Technescan™, Curium™ and the Curium logo are trademarks of a Curium company.

A09110

Revised: 11/2025

CURIUM™

**Technescan™ PYP™**  
**(Kit for the Preparation of Technetium Tc 99m Pyrophosphate Injection)**  
*For Intravenous Use*

**DESCRIPTION**

**Drug Characteristics**

Technescan™ PYP™ (kit for the preparation of technetium Tc 99m pyrophosphate injection) is a radioactive diagnostic drug for intravenous use after radiolabeling with sodium pertechnetate Tc 99m injection or after reconstitution with 0.9% sodium chloride injection in conjunction with sodium pertechnetate Tc 99m injection.

Each vial contains 11.9 mg sodium pyrophosphate, 3.2 mg (minimum) stannous chloride (SnCl<sub>2</sub>•2H<sub>2</sub>O), and 4.4 mg (maximum) total tin expressed as stannous chloride (SnCl<sub>2</sub>•2H<sub>2</sub>O). Prior to lyophilization, the pH is adjusted with hydrochloric acid. The pH of the reconstituted drug is between 4.5 and 7.5. No bacteriostatic preservative is present. The vial contains a sterile, non-pyrogenic, lyophilized powder packaged under nitrogen.

The precise structures of the stannous-pyrophosphate and technetium Tc 99m pyrophosphate complexes are not known.

**Nuclear Physical Characteristics**

Technetium-99m decays by isomeric transition with a physical half-life of 6.02 hours. The principal photon that is useful for detection and imaging is listed in Table 1.

**Table 1. Principal Radiation Emission Data**

Radiation	Mean % per Disintegration	Energy (keV)
Gamma-2	89.07	140.5

The specific gamma ray constant for technetium-99m is 0.795 R/hr-mCi at 1 cm. The first half-value layer is 0.023 cm of lead (Pb). A range of values for the relative attenuation of the radiation emitted by this radionuclide that results from interposition of various thicknesses of Pb is shown in Table 2. For example, the use of 0.27 cm thickness of Pb will attenuate the external radiation emitted by a factor of about 1,000.

**Table 2. Radiation Attenuation by Lead Shielding**

Shield Thickness (Pb) cm	Coefficient of Attenuation
0.023	0.5
0.09	10 <sup>-1</sup>
0.18	10 <sup>-2</sup>
0.27	10 <sup>-3</sup>

To correct for physical decay of this radionuclide, the fractions that remain at selected time intervals after the time of calibration are shown in Table 3.

**Table 3. Physical Decay Chart; Technetium-99m, Half-Life 6.02 Hours**

Hours	Fraction Remaining	Hours	Fraction Remaining
0*	1	7	0.447
1	0.891	8	0.398
2	0.794	9	0.355
3	0.708	10	0.316
4	0.631	11	0.282
5	0.562	12	0.251
6	0.501		

\*Calibration Time

## CLINICAL PHARMACOLOGY

### Skeletal and Cardiac Imaging

When injected intravenously, technetium Tc 99m pyrophosphate has a specific affinity for areas of altered osteogenesis. It is also concentrated in the injured myocardium, primarily in areas of irreversibly damaged myocardial cells.

One to 2 hours after intravenous injection of technetium Tc 99m pyrophosphate, an estimated 40% to 50% of the injected dose is taken up by the skeleton, and approximately 0.01% to 0.02% of the injected dose is taken up per gram of acutely infarcted myocardium. Within a period of 1 hour, 10% to 11% remains in the vascular system, declining to approximately 2% to 3% 24 hours after injection. The average urinary excretion is approximately 40% of the administered dose after 24 hours.

### Gated Cardiac Blood Pool and Gastrointestinal Bleed Imaging

Technescan PYP also has an affinity for red blood cells. When Technescan PYP reconstituted in 0.9% sodium chloride injection is administered 15 minutes to 30 minutes prior to the intravenous administration of sodium pertechnetate Tc 99m injection for red blood cell labeling, approximately 75% of the administered activity remains in the blood pool to allow imaging of the cardiac chambers. When the modified in vivo/in vitro red blood cell labeling method is used, comparable percentages of the injected radioactivity are obtained.

## INDICATIONS AND USAGE

Technescan PYP, after radiolabeling with sodium pertechnetate Tc 99m, is indicated for:

- Skeletal imaging to demonstrate areas of altered osteogenesis in adults

- Cardiac imaging as an adjunct in the diagnosis of acute myocardial infarction in adults (See **WARNINGS**)

Technescan PYP, in conjunction with sodium pertechnetate Tc 99m injection for red blood cell (RBC) labeling, is indicated for gated cardiac blood pool imaging and for the detection of gastrointestinal bleeding sites in adults.

## CONTRAINDICATIONS

None known.

## WARNINGS

Image interpretation errors can occur. As an adjunct in the diagnosis of confirmed myocardial infarction (ECG and serum enzymes positive), the estimate of false negative image interpretations was 6%. False negative image interpretations can occur if made too early in the evolutionary phase of the infarct or too late in the resolution phase. In a study involving 22 patients in whom ECG was positive and serum enzymes questionable or negative, but in whom the final diagnosis of acute myocardial infarction was made, the estimates of false negative and false positive image interpretations were 23% and 9%, respectively. False positive image interpretations have been reported following coronary artery bypass graft surgery and in unstable angina pectoris, old myocardial infarcts, and cardiac contusions.

Technetium Tc 99m pyrophosphate may impair brain imaging with sodium pertechnetate Tc 99m and result in false positive or false negative image interpretation. It is recommended, where feasible, that brain imaging precede skeletal imaging procedures.

Gated cardiac blood pool and gastrointestinal bleed imaging may be impaired in patients receiving sodium heparin for anticoagulant therapy. This is characterized by a reduction in the amount of injected radioactivity remaining in the blood pool. Avoid heparinized catheter systems for administration of Technescan PYP.

The biodistribution of technetium Tc 99m pyrophosphate may be altered in the presence of high levels of certain cations (iron, calcium, and aluminum). This may result in reduced uptake of radionuclide in the skeleton and increased extraosseal uptake, which may potentially degrade imaging quality. High levels of these cations may be caused by concomitant medications or medical conditions (e.g., iron overload, hypercalcemia, etc.). Most cases are observed after iron infusion. (See **PRECAUTIONS, Drug Interactions.**)

## PRECAUTIONS

### General

Technetium Tc 99m pyrophosphate contributes to a patient's overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk of cancer. Ensure safe drug handling to protect patients and healthcare providers from

unintentional radiation exposure. (See **DOSAGE AND ADMINISTRATION, Radiation Safety-Drug Handling.**) Advise patients to drink fluids before and after administration and to void as often as possible after administration to reduce unnecessary exposure to radiation.

### **Drug Interactions**

The biodistribution of technetium Tc 99m pyrophosphate may be altered in the presence of high levels of certain cations (iron, calcium, and aluminum). This may result in reduced uptake of radionuclide in the skeleton and increased extraosseal uptake, which may potentially degrade imaging quality. In patients with high levels of these cations caused by concomitant medications, particularly patients receiving iron infusions, consider performing an imaging study with technetium Tc 99m pyrophosphate injection once the cation levels have normalized (e.g., after 3 to 5 half-lives of the cation). (See **WARNINGS.**)

### **Carcinogenesis, Mutagenesis, Impairment of Fertility**

No long-term animal studies have been performed to evaluate carcinogenic or mutagenic potential, or whether this drug affects fertility in males or females.

### **Pregnancy**

Animal reproduction studies have not been conducted with Technetium Tc 99m Pyrophosphate Injection. It is also not known whether this drug can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity.

All radiopharmaceuticals, including Technescan PYP, have the potential to cause fetal harm depending on the fetal stage of development and the magnitude of the radiation dose. If considering Technescan PYP administration to a pregnant woman, inform the patient about the potential for adverse pregnancy outcomes based on the radiation dose from technetium Tc 99m pyrophosphate and the gestational timing of exposure.

### **Nursing Mothers**

Technetium-99m is excreted in human milk during lactation, therefore, formula feedings should be substituted for breast feeding.

### **Pediatric Use**

Safety and effectiveness in pediatric patients have not been established.

### **Geriatric Use**

Of the 137 subjects included in clinical studies of Technescan PYP labeled with technetium-99m for skeletal imaging, 28 subjects (20%) were 65 to 74 years of age, and 21 (15%) were 75 years of age and older. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences between elderly and younger patients.

This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

## **ADVERSE REACTIONS**

The following adverse reactions associated with the use of Technescan PYP have been reported: flushing, hypotension, fever, chills, nausea, vomiting, and dizziness, as well as hypersensitivity reactions such as itching and various skin rashes.

## **OVERDOSAGE**

In case of overdose of Technetium Tc 99m Pyrophosphate Injection, encourage patients to maintain hydration and to void frequently to minimize radiation exposure.

## **DOSAGE AND ADMINISTRATION**

### **Radiation Safety – Drug Handling**

After radiolabeling of Technescan PYP, the reaction vial contains Technetium Tc 99m Pyrophosphate Injection. Handle Technetium Tc 99m Pyrophosphate Injection with appropriate safety measures to minimize radiation exposure. (See **PRECAUTIONS, General.**) Use waterproof gloves, effective radiation shielding, and other appropriate safety measures when preparing and handling Technetium Tc 99m Pyrophosphate Injection.

Radiopharmaceuticals should be used by or under the control of healthcare providers who are qualified by specific training and experience in the safe use and handling of radionuclides, and whose experience and training have been approved by the appropriate governmental agency authorized to license the use of radionuclides.

### **Recommended Dosage, Administration, and Imaging Instructions for Skeletal and Cardiac Imaging**

#### Dosing and Administration Instructions

- The recommended activity of Technetium Tc 99m Pyrophosphate Injection for each type of imaging is presented in Table 4.
- Administer Technetium Tc 99m Pyrophosphate Injection intravenously over 10 seconds to 20 seconds.
- Measure the patient dose with a dose calibrator immediately before administration.
- If not contraindicated by patient's condition, encourage patients to drink fluids before and after administration and void as often as possible to reduce unnecessary radiation exposure.

- For radiolabeling instructions, see **Directions for Drug Preparation**, Procedure for the Preparation of Technetium Tc 99m Pyrophosphate Injection.

**Table 4. Recommended Administered Activity of Technetium Tc 99m Pyrophosphate Injection for Skeletal and Cardiac Imaging in Adults**

Indication	Activity of Technetium Tc 99m Pyrophosphate	Fraction of Vial Contents Required for Pyrophosphate
Skeletal Imaging	185 MBq to 555 MBq (5 mCi to 15 mCi)	0.07 to 0.91
Cardiac Imaging	370 MBq to 555 MBq (10 mCi to 15 mCi)	0.26 to 0.45

### Skeletal Imaging

Begin imaging 1 hour to 6 hours following administration.

### Cardiac Imaging

- The patient's cardiac condition should be stable before beginning the cardiac imaging procedure.
- Begin imaging 60 minutes to 90 minutes following administration. The acute myocardial infarct can be visualized from 24 hours to 9 days following onset of symptoms, with maximum localization at 48 to 72 hours. Cardiac imaging should be done with a gamma scintillation camera. It is recommended that images include anterior, left anterior oblique, and left lateral projections.
- Interference from chest wall lesions such as breast tumors and healing rib fractures can be minimized by employing the three recommended projections.

### **Recommended Dosage, Administration, and Imaging Instructions for Gated Cardiac Blood Pool and Gastrointestinal Bleed Imaging**

#### Dose

The recommended dose of Technescan PYP reconstituted in 0.9% sodium chloride injection for gated cardiac blood pool and gastrointestinal bleed imaging in adults is 1 mL, followed by 555 MBq to 740 MBq (15 mCi to 20 mCi) of sodium pertechnetate Tc 99m injection.

#### Administration Instructions for In Vivo RBC Labeling Method

- Reconstitute Technescan PYP with 0.9% sodium chloride injection. (See **Directions for Drug Preparation**, Procedure for the Reconstitution of Technescan PYP.)
- Administer the patient dose of reconstituted Technescan PYP intravenously by direct

venipuncture. Do not use heparinized catheters. (See **WARNINGS**.)

- c. Wait 15 minutes to 30 minutes.
- d. Administer sodium pertechnetate Tc 99m injection intravenously.

#### Administration Instructions for Modified In Vivo/In Vitro RBC Labeling Method Using ACD

- a. Reconstitute Technescan PYP with 0.9% sodium chloride injection. (See **Directions for Drug Preparation**, Procedure for the Reconstitution of Technescan PYP.)
- b. Administer the patient dose of reconstituted Technescan PYP intravenously by direct venipuncture. Do not use heparinized catheters. (See **WARNINGS**.)
- c. Insert an intravenous line with a 3-way stopcock in a large peripheral vein and maintain the line with a continuous drip of 0.9% sodium chloride injection.
- d. 30 minutes post-injection:
  - Clear the line by withdrawing and discarding approximately 5 mL of blood.
  - Then draw approximately 5 mL of blood into a syringe containing 1 mL preservative-free acid-citrate-dextrose (ACD) and 555 MBq to 740 MBq (15 mCi to 20 mCi) of sodium pertechnetate Tc 99m injection.
  - Turn the stopcock, flush the line, and adjust the flow of 0.9% sodium chloride injection.
- e. Gently rotate syringe to mix and incubate at room temperature for 10 minutes.
- f. Inject the mixture via the 3-way stopcock.

#### Administration Instructions for Modified In Vivo/In Vitro RBC Labeling Method Using Heparin

- a. Reconstitute Technescan PYP with 0.9% sodium chloride injection. (See **Directions for Drug Preparation**, Procedure for the Reconstitution of Technescan PYP.)
- b. Administer the patient dose of reconstituted Technescan PYP intravenously by direct venipuncture. Do not use heparinized catheters. (See **WARNINGS**.)
- c. Insert an infusion set fitted with a 3-way stopcock in a large peripheral vein, and heparinize the intravenous line with 0.9% sodium chloride injection containing 5 units/mL to 10 units/mL of preservative-free heparin.
- d. Thirty minutes after Technescan PYP injection, draw 3 mL of blood into a syringe containing 555 MBq to 740 MBq (15 mCi to 20 mCi) of sodium pertechnetate Tc 99m injection. Anticoagulation of the blood is provided by residual heparin in the intravenous

line.

- e. Gently rotate the syringe to mix and incubate at room temperature for 10 minutes.
- f. Inject the mixture via the 3-way stopcock.

### Gated Cardiac Blood Pool Imaging

Begin cardiac imaging 10 minutes following the administration of sodium pertechnetate Tc 99m injection (in vivo method) or Tc 99m labeled red blood cells (modified in vivo/in vitro method) utilizing a scintillation camera interfaced to an electrocardiographic gating device.

### Gastrointestinal Bleed Imaging

The imaging of gastrointestinal bleeding is dependent on factors such as the region of imaging, rate and volume of the bleed, efficacy of labeling of the red blood cells, and timeliness of imaging. Acquire sequential images over a period of time until a positive image is obtained or clinical conditions warrant the discontinuance of the procedure. The period of time for collecting the images may range up to 36 hours.

## **Directions for Drug Preparation**

### Procedural Precautions

- The contents of the Technescan PYP reaction vial may be used for the preparation of Technetium Tc 99m Pyrophosphate Injection. Technescan PYP may also be reconstituted with preservative-free 0.9% sodium chloride injection and injected intravenously prior to labeling of red blood cells with sodium pertechnetate Tc 99m injection using either the in vivo or modified in vivo/in vitro method.
- The components of the kit are sterile and non-pyrogenic. It is essential that the user follow the directions carefully and adhere to strict aseptic procedures during preparation.
- Wear waterproof gloves during the entire preparation procedure and during subsequent patient dose withdrawals from the reaction vial.
- Make all withdrawals and administration of sodium pertechnetate Tc 99m injection with an adequately shielded syringe.
- Keep the prepared Technetium Tc 99m Pyrophosphate Injection in the lead shield described below (with cap in place) during the useful life of the radioactive preparation. Make all withdrawals and administration of the Technetium Tc 99m Pyrophosphate Injection with an adequately shielded syringe.
- Any sodium pertechnetate Tc 99m injection that contains an oxidizing agent is not suitable for use in the preparation of Technetium Tc 99m Pyrophosphate Injection.

### Procedure for the Preparation of Technetium Tc 99m Pyrophosphate Injection

1. Remove a Technescan PYP reaction vial from the refrigerator and allow the vial contents to come to room temperature, 20°C to 25°C (68°F to 77°F), for approximately 5 minutes.
2. Attach the radioassay information label with radiation warning symbol to the reaction vial and place the vial in a lead Dispensing Shield fitted with a lead cap and having a minimum wall thickness of 1/8 inch. Do not remove the reaction vial from the Dispensing Shield, except temporarily, for Step 5 below.
3. Add 1 mL to 10 mL of sodium pertechnetate Tc 99m injection to the reaction vial. In choosing the amount of the sodium pertechnetate Tc 99m injection radioactivity to be used in the preparation of the Technetium Tc 99m Pyrophosphate Injection, the labeling efficiency, number of patients, administered radioactive dose, and radioactive decay must be taken into account. The recommended maximum activity of sodium pertechnetate Tc 99m injection to be added to the reaction vial is 3,700 MBq (100 mCi).
4. With the reaction vial in the Dispensing Shield (with cap in place), shake sufficiently to bring the lyophilized material into solution. Allow to stand for 5 minutes at room temperature.
5. Using proper shielding, visually inspect the reaction vial. The resulting solution should be clear and free of particulate matter. If not, do not use the product.
6. Assay the product in a suitable calibrator and record the time, date of preparation, and the activity of the Technetium Tc 99m Pyrophosphate Injection onto the radioassay information label.
7. Check the radiochemical purity prior to administration.
8. Store the reaction vial in the Dispensing Shield at 20°C to 25°C (68° to 77°F). Use within 6 hours of radiolabeling.
9. Dispose of unused drug in a safe manner in accordance with applicable regulations.

### Procedure for the Reconstitution of Technescan PYP

- a. Remove a Technescan PYP reaction vial from the refrigerator and allow the vial contents to come to room temperature, 20°C to 25°C (68°F to 77°F), for approximately 5 minutes.
- b. Add 3 mL of preservative-free 0.9% sodium chloride injection to the reaction vial.
- c. Shake the reaction vial sufficiently to bring the lyophilized material into solution. Allow to stand for 5 minutes at room temperature.
- d. Visually inspect the reaction vial. The resulting solution should be clear and free of particulate matter. If not, do not use the product.

- e. Store the reconstituted reaction vial upright at 20°C to 25°C (68°F to 77°F). Use within 6 hours of reconstitution.

## Radiation Dosimetry

### Skeletal and Cardiac Imaging

Estimated absorbed radiation doses from an intravenous injection of Technetium Tc 99m Pyrophosphate Injection in adults are shown in Table 5.

**Table 5. Estimated Absorbed Radiation Doses in Organs and Tissues in Adults Who Received Technetium Tc 99m Pyrophosphate Injection**

Organ/Tissue	Absorbed Dose per Unit Activity Administered (mGy/MBq)
Skeleton*	0.010
Bone Marrow	0.008
Kidneys	0.038
Total Body	0.002
Bladder	
2-hr. void	0.026
4.8-hr. void	0.062
Testes	
2-hr. void	0.003
4.8-hr. void	0.004
Ovaries	
2-hr. void	0.003
4.8-hr. void	0.004
Heart	
Normal	0.002
Impaired	0.004

\*Dose at point of highest uptake may be a factor of 10 higher.

### Gated Cardiac Blood Pool and Gastrointestinal Bleed Imaging

Estimated absorbed radiation doses from an intravenous administration of sodium pertechnetate Tc 99m injection, 30 minutes after the intravenous administration of Technescan PYP are shown in Table 6.

**Table 6. Estimated Absorbed Radiation Doses in Adults Who Received Sodium Pertechnetate Tc 99m Injection 30 minutes after Technescan PYP Administration\***

Organ/Tissue	Absorbed Dose per Unit Activity Administered (mGy/MBq)
--------------	--

Bladder Wall	0.009
Ovaries	0.006
Testes	0.004
Red Marrow	0.005
Spleen**	0.004
Blood	0.014
Total Body	0.004

\*Assumes non-resting state, with 75% of the sodium pertechnetate Tc 99m labeling red blood cells and the other 25% remaining as pertechnetate.

\*\*Assumes no initial uptake in spleen.

## HOW SUPPLIED

Technescan PYP (kit for the preparation of technetium Tc 99m pyrophosphate injection) contains 11.9 mg sodium pyrophosphate as a white lyophilized powder in a multiple-dose vial.

Technescan PYP is available in cartons of 5 vials (NDC 69945-094-20).

Before preparation, store the Technescan PYP reaction vial refrigerated at 2°C to 8°C (36°F to 46°F).

After preparation, store the vial at 20°C to 25°C (68°F to 77°F) [see USP Controlled Room Temperature]. If radiolabeled, store the vial in appropriate shielding to protect from radiation. Use within 6 hours of preparation.

Dispose of unused Technetium Tc 99m Pyrophosphate Injection in accordance with appropriate regulations.

This reagent kit is for distribution to persons licensed by the U.S. Nuclear Regulatory Commission or the relevant regulatory authority of an Agreement State.

Manufactured by:  
 Curium US LLC  
 2703 Wagner Place  
 Maryland Heights, MO 63043

Made in USA

©2025 Curium US LLC. Technescan™ PYP™, Curium™, and the Curium logo are trademarks of a Curium company.

A094I0

Revised: 11/2025

CURIUM™